Day One Biopharmaceuticals, INC Form 4 insider transactions

Day One Biopharmaceuticals' General Counsel, Adam Dubow, reported the acquisition of shares through vesting of Restricted Stock Units (RSUs) and subsequent sale of some shares to cover tax liabilities.

Charles N. York II, COO, CFO, and Secretary of Day One Biopharmaceuticals, reported the acquisition of shares through RSU vesting and subsequent sale of shares to cover tax obligations.

Day One Biopharmaceuticals' Head of R&D, Samuel C. Blackman, sold a total of 28,255 shares of common stock in two transactions under a pre-arranged 10b5-1 trading plan.

Samuel C. Blackman, Head of R&D at Day One Biopharmaceuticals, sold 11,245 shares of common stock at an average price of $16.0326 per share under a pre-arranged trading plan.

Samuel C. Blackman, Head of R&D at Day One Biopharmaceuticals, sold 500 shares of common stock at an average price of $16.02, according to a Form 4 filing.

Samuel C. Blackman, Head of R&D at Day One Biopharmaceuticals, sold 30,000 shares of common stock at an average price of $14.2225.

Adam Dubow, General Counsel of Day One Biopharmaceuticals, reports the acquisition and disposal of common stock and Restricted Stock Units (RSUs) to cover tax liabilities.

Charles N. York II, COO, CFO, and Secretary of Day One Biopharmaceuticals, Inc., reported the acquisition and disposal of common stock and Restricted Stock Units (RSUs) on August 15 and 16, 2024.

Samuel C. Blackman, Head of R&D at Day One Biopharmaceuticals, reports the acquisition and disposition of common stock and restricted stock units to cover tax liabilities.

CEO Jeremy Bender reports acquisition and disposal of Day One Biopharmaceuticals stock, including transactions related to tax liability and RSU settlements.

AI Day1 LLC, along with related entities, reports acquiring warrants to purchase 827,586 shares of Day One Biopharmaceuticals common stock.

Samuel Blackman, Head of R&D at Day One Biopharmaceuticals, sold 20,000 shares of common stock at an average price of $16.0113 on July 16, 2024, according to a Form 4 filing.

CEO Jeremy Bender reports changes in beneficial ownership of Day One Biopharmaceuticals stock due to annuity payments from grantor retained annuity trusts to a revocable trust.

Director Saira Ramasastry sold 10,000 shares of Day One Biopharmaceuticals, Inc. (DAWN) at an average price of $13.1877 on June 21, 2024.

Samuel Blackman, Head of R&D at Day One Biopharmaceuticals, sold 30,000 shares of common stock at an average price of $12.6196 on June 10, 2024, according to a Form 4 filing.

Director J. Scott Garland acquired 32,335 stock options in Day One Biopharmaceuticals on May 23, 2024, according to a Form 4 filing.

William Grossman, a director at Day One Biopharmaceuticals, acquired stock options for 32,335 shares on May 23, 2024.

Director Saira Ramasastry acquired stock options in Day One Biopharmaceuticals, Inc. on May 23, 2024.

Garry A. Nicholson, a director of Day One Biopharmaceuticals, acquired stock options for 32,335 shares of common stock on May 23, 2024.

Director John A. Josey reports the acquisition of stock options in Day One Biopharmaceuticals, Inc.

Natalie C. Holles, a director of Day One Biopharmaceuticals, acquired stock options to purchase 32,335 shares of common stock on May 23, 2024.

Michael Gladstone, a director at Day One Biopharmaceuticals, acquired stock options for 32,335 shares on May 23, 2024.

Director Habib J. Dable acquired 32,335 stock options in Day One Biopharmaceuticals, Inc. on May 23, 2024.

CEO Jeremy Bender reports acquisition and disposal of Day One Biopharmaceuticals stock, including transactions related to RSU settlements and tax liabilities.

Samuel C. Blackman, Head of R&D at Day One Biopharmaceuticals, reports acquisition and disposal of company stock and derivative securities to cover tax liabilities.

Charles N. York II, COO, CFO, and Secretary of Day One Biopharmaceuticals, Inc., reported the acquisition and disposal of common stock and Restricted Stock Units (RSUs) on May 15 and 16, 2024.

Adam Dubow, General Counsel of Day One Biopharmaceuticals, reports the acquisition and disposal of common stock and Restricted Stock Units (RSUs) to cover tax liabilities.

Samuel C. Blackman, Head of R&D at Day One Biopharmaceuticals, sold 10,000 shares of common stock at an average price of $16.3743 per share, pursuant to a pre-arranged Rule 10b5-1 trading plan.

Day One Biopharmaceuticals CEO Jeremy Bender sold shares of the company's common stock between May 1 and May 3, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Charles N. York II, COO, CFO, and Secretary of Day One Biopharmaceuticals, Inc., sold shares of common stock between May 1st and May 3rd, 2024, under a pre-arranged Rule 10b5-1 trading plan.